Nurix Therapeutics Announces FDA Clearance for GS-6791/NX-0479 IND, Phase 1 Trials Set to Begin in Q2 2025 in Collaboration with Gilead Sciences April 17, 2025 — 07:13 am EDT.

There were number of other less serious advisories issued around the NS-OX and Nexus switch portfolio as well. They included one that described a vulnerability in the NX-API feature of Cisco NX-OS ...